A Year In Review
The TPD field is experiencing unprecedented growth, with the number of assets skyrocketing from just 21 in 2014 to 398 in 2024. Breakthroughs in PROTACs, molecular glues, and emerging degradation technologies are pushing the field forward, with novel modalities such as DUB inhibitors and protein proximity inducers gaining momentum.
Despite challenges in clinical translation, 2024 saw significant milestones, including the approval of Inavolisib for endocrine-resistant breast cancer and the first TPD therapy for Parkinson’s disease entering the clinic. As investments shift towards next-generation modalities, the industry is poised for further innovation.
This Report Contains
Stay ahead of the curve with the Beacon TPD 2024 Landscape Review. This report delivers exclusive insights into drug development, trial activity, investment trends, and regulatory shifts that are shaping the future of TPD. Whether you’re a biotech leader, investor, or researcher, this report is packed with the data-driven intelligence you need to make informed decisions and seize new opportunities. Download now to gain the competitive edge.
Previous TPD Landscape Reviews
TPD 2024 H1 Landscape Review
An analysis of the TPD landscape in H1 of 2024
You May Also Be Interested In…
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
